Association of New Generation Anti-CCP Antibodies with Disease Severity and Functional Status in Rheumatoid Arthritis Patients
Main Article Content
Abstract
Introduction: Detection of anti-cyclic citrullinated peptide (anti-CCP) antibodies in patients with rheumatoid arthritis (RA) is associated with higher disease activity and lower functional ability. This study investigated the presence of the new generation of anti-CCP antibodies (anti-CCP2 IgG, anti-CCP2 IgA and anti-CCP3.1 IgG/IgA) and their asso- ciation with disease severity and functional status of RA patients. Methods: A total of 46 RA patients and 40 healthy controls participated in this cross-sectional study that was conducted at the Rheumatology Clinic, Hospital Universiti Sains Malaysia. Blood samples were taken from all participants for anti-CCP2 IgG, anti-CCP2 IgA, and anti-CCP3.1 IgG/IgA analysis. Disease severity and functional status of RA patients were measured using the Disease Activity Score-28 (DAS28) and the modified Health Assessment Questionnaire (mHAQ) respectively. Results: Significant- ly higher proportion of RA patients were found with positive anti-CCP2 IgG (63.0%), anti-CCP2 IgA (37.0%), and anti-CCP3.1 IgG/IgA antibodies (63.0%) than the healthy controls. No significant association was found between anti-CCP antibodies status and mean DAS28 score of the RA patients. However, RA patients with negative anti-CCP2 IgG status had higher mean mHAQ score than patients with positive anti-CCP2 IgG status. Conclusion: Our study has demonstrated detection of the new generation anti-CCP antibodies in RA patients, supporting the use of autoan- tibodies in RA diagnosis. While no significant association was found between the presence of anti-CCP antibodies and disease severity of RA patients, the absence of anti-CCP2 IgG was associated with worse function and greater disability of the patients.
Downloads
Article Details
References
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69: 1580-8. doi:10.1136/ard.2010.138461
Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019; 33: 101477. doi: 10.1016/j. berh.2019.
Sieghart D, Platzer A, Studenic P, et al. Determination of autoantibody isotypes increases the sensitivity of serodiagnostics in rheumatoid arthritis. Front Immunol. 2018; 9: 876. doi: 10.3389/fimmu.2018.00876.
de Brito Rocha S, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol. 2019; 59:
doi: 10.1186/s42358-018-0042-8.
van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011; 7: 391-8. doi: 10.1038/ nrrheum.2011.76.
Vos I, Van Mol C, Trouw LA, et al. Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. Clin Rheumatol. 2017; 36: 1487-92. doi: 10.1007/ s10067-017-3684-8.
dos Anjos LM, Pereira IA, d ‘Orsi E, Seaman AP, Burlingame RW, Morato EF. A comparative study of IgG second- and third-generation anti- cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol. 2009; 28: 153-8. doi: 10.1007/ s10067-008-0999-5.
Swart A, Burlingame RW, Gürtler I, Mahler M. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clin Chim Acta. 2012; 414: 266-72. doi: 10.1016/j.cca.2012.09.015.
Szekanecz Z, Szabó Z, Zeher M, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res. 2013; 56: 439-43. doi: 10.1007/s12026-013-8425-8.
Farheen K, Agarwal SK. Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manag Care Pharm. 2011; 17: S09-13. doi: 10.18553/jmcp.2011.17.s9-b.s09.
Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesawakit P, Muengchan C. Associations of rheumatoid factor and anti- citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int. 2015; 35: 1693-9. doi: 10.1007/s00296-015-3271-8.
Hamad MB, Marzouk S, Kaddour N, et al. Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity. J Clin Lab Anal. 2014; 28: 21-
doi: 10.1002/jcla.21638
Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj- Hassouni N. Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life. Clin Rheumatol. 2012; 31: 329-34. doi: 10.1007/s10067-011-
-4.
Samanci N, Ozdem S, Akbas H, et al. Diagnostic value and clinical significance of anti-CCP in
patients with advanced rheumatoid arthritis. J Natl Med Assoc. 2005; 97: 1120-6.
van der Heijde DM, van ‘t Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993; 20: 579-81.
Pincus T, Yazici Y, Bergman M. Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol. 2005; 23: S19-28.
Goeldner I, Skare TL, de Messias Reason IT, Nisihara RM, Silva MB, Utiyama SR. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology (Oxford). 2010; 49:
-3. doi: 10.1093/rheumatology/keq134.
Marcos J, Waimann C, Dal Pra F, et al. General characteristics of an early arthritis cohort in Argentina. Jan.: Rheumatology (Oxford). 2011; 50(1): 110-6. doi: 10.1093/rheumatology/keq220.
Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int. 2008; 28: 965-70. doi: 10.1007/s00296-008-
-3
Nicaise-Roland P, Nogueira L, Demattei C, et al. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis. 2013; 72: 357-62. doi: 10.1136/ annrheumdis-2011-201056.
Reed E, Hedström AK, Hansson M, et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther. 2020; 22:
doi: 10.1186/s13075-020-02191-2.
Syversen SW, Gaarder PI, Goll GL, et al. High anti- cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2008; 67: 212-7. doi: 10.1136/ard.2006.068247.
Shahrir M, Shahdan M, Shahid M, et al. Multicentre survey of rheumatoid arthritis patients from Ministry of Health rheumatology centres in Malaysia. Int J Rheum Dis. 2008; 11: 287–92. https://doi. org/10.1111/j.1756-185X.2008.00379.x
Berens HM, Polinski KJ, Mikuls TR, et al. Anticyclic citrullinated peptide antibodies 3.1 and anti-CCP-IgA are associated with increasing age in individuals without rheumatoid arthritis. J Rheumatol. 2019; 46: 1556-9. DOI: https://doi. org/10.3899/jrheum.180897